Showing results (121-130 of 762) with videos related to
Sort By:
Pageof 77
Journal of the American Society of Nephrology : JASN|February 3, 2023
Intensive BP Control in Patients with CKD and Risk for Adverse OutcomesElaine Ku, Charles E McCulloch, Lesley A Inker, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2023
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort StudyPiero Ruggenenti, Linda Reinhard, Barbara Ruggiero, et al.Journal of the American Society of Nephrology : JASN|March 26, 2015
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous NephropathyPiero Ruggenenti, Hanna Debiec, Barbara Ruggiero, et al.Eclinicalmedicine|January 10, 2022
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomesPiero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, et al.Plos One|July 17, 2024
GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniquesFabiola Carrara, Flavio Gaspari, Matias Trillini, et al.The New England Journal of Medicine|January 27, 2006
Long-term outcome of renal transplantation from older donorsGiuseppe Remuzzi, Paolo Cravedi, Annalisa Perna, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2013
In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody developmentMarta Todeschini, Monica Cortinovis, Norberto Perico, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress reportLuca Antiga, Marina Piccinelli, Giorgio Fasolini, et al.Diabetes Care|June 23, 2010
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trialPiero Ruggenenti, Dario Cattaneo, Stefano Rota, et al.Blood|July 20, 2002
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndromeGiuseppe Remuzzi, Miriam Galbusera, Marina Noris, et al.Pageof 77